Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636061 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
A Phase 2 study, sponsored by Oyster Point Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
NCT03636061 is a Phase 2 study that has completed, run by Oyster Point Pharma. The registered enrollment target is 182 participants.
The verdict
NCT03636061, a Phase 2 study, has completed, sponsored by Oyster Point Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease
Interventions
- DRUG Placebo (vehicle) nasal spray
- DRUG OC-01 (varenicline) nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2018-08-15 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636061
The ClinicalTrials.gov registry entry for NCT03636061 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oyster Point Pharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (vehicle) nasal spray is the first listed.
NCT03636061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03636061 about?
NCT03636061 is a clinical study titled "Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease". The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease
What is the current status of trial NCT03636061?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2018-08-15. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT03636061?
The interventions under investigation include: Placebo (vehicle) nasal spray (DRUG), OC-01 (varenicline) nasal spray (DRUG).
Who is sponsoring clinical trial NCT03636061?
This trial is sponsored by Oyster Point Pharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.